candidiasis
CANDIDIASIS
Candida sp are the most common cause of fungal infections.
 It can cause infections that range from benign mucocutaneous illnesses to invasive process that may affect any organ.
 It is considered as normal flora in the gastrointestinal and genitourinary tracts, but when there is an imbalance in the ecological niche, they can invade and cause disease.
Most common risk factors include broad-spectrum antibiotic use, central venous catheter use, receipt of parenteral nutrition, receipt of renal placement therapy by patients in ICUs, neutropenia, implantable prosthetic device use and receipt of immunosuppressive agents.
Drug Information

Indication: Invasive candidiasis, including candidemia in adults.

Indication: Invasive aspergillosis; fluconazole-resistant serious invasive Candida infections (eg, C krusei); serious...

Indication: For adult & childn ≥12 mth: Empirical therapy for presumed fungal infections in febrile, neutropenic pa...

Indication: Relief of external thrush symptoms.

Indication: Candida spp skin infections in which inflammatory symptoms are prominent. Mycotic affections w/ bacterial supe...

Indication: Dermatophytoses, mycoses & various fungi, pityriasis versicolor, infection & superinfection (gm +ve). ...

Indication: Oropharyngeal cavity & GIT candidosis in adults & ped >6 mth.

Endix
econazole nitrate + triamcinolone acetonide

Indication: Dermatophytosis: Tinea pedis, tinea corporis, tinea capitis, tinea cruris, tinea barbae. Tinea versicolor, can...

Indication: Invasive candidiasis in childn & adults. Oesophageal candidiasis in adults, adolescents ≥16 yr & el...

Indication: Topical treatment of dermatophyte skin infections eg, tinea corporis, tinea cruris, tinea manus & tinea pe...

1  /  12
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 06 Aug 2019
The guideline-recommended, single-tablet, fixed-dose regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) was noninferior to the dolutegravir and F/TAF (D/F/TAF) regimen in persons living with HIV (PLHIV), according to data presented at IAS 2019.